Prostate cancer most often develops from prostatic intraepithelial neoplasia (PIN) in the prostate gland and can be described as localised, locally advanced or advanced (metastatic). Symptoms may include genito-urinary symptoms such as poor urinary stream and erectile dysfunction, or bone pain in cases where the disease has spread to the bones.
Featured Learning Zones
Prostate cancer is considered a slow growing cancer and is driven by the androgen axis. Subsequently, treatment for hormone sensitive prostate cancer (HSPC) revolves around androgen deprivation therapy (ADT) alongside radiation therapy and chemotherapy.
Related news and insights
Exelixis, Inc. announced detailed results from CONTACT-02, a phase III pivotal study evaluating cabozantinib (Cabometyx) in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT
Pfizer Inc. announced that the European Commission (EC) has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Talzenna